<?xml version="1.0" encoding="UTF-8"?>
<p>According to the median value of the TME scores, respectively, 502 patients in TCGA-HNSC data set were stratified into the high- or low-score group. All TME scores analyses did not find a significant correlation with survival (
 <italic>P</italic> &gt; 0.05) (
 <xref ref-type="fig" rid="f2">
  <bold>Figures 2A–C</bold>
 </xref>). However, we can observe a tendency that patients with higher immune scores have a better prognosis (
 <xref ref-type="fig" rid="f2">
  <bold>Figure 2A</bold>
 </xref>). In addition, we found that female patients had a significantly worse prognosis than male patients (
 <italic>P</italic> &lt; 0.05) (
 <xref ref-type="fig" rid="f2">
  <bold>Figure 2D</bold>
 </xref>). There was a significant correlation between immune score and T stage (
 <italic>P</italic> &lt; 0.05) (
 <xref ref-type="fig" rid="f2">
  <bold>Figure 2E</bold>
 </xref>). Immune scores of tumor tissues were significantly lower in male patients than in female patients (
 <italic>P</italic> &lt; 0.05) (
 <xref ref-type="fig" rid="f2">
  <bold>Figure 2F</bold>
 </xref>). No correlation between tumor immune score and lymph node metastasis in patients was found (
 <xref ref-type="supplementary-material" rid="SF1">
  <bold>Figure S1A</bold>
 </xref>). No significant correlation between tumor StromalScore and any clinical features was found in TCGA-HNSC data set (
 <italic>P</italic> &gt; 0.05) (
 <xref ref-type="supplementary-material" rid="SF1">
  <bold>Figures S1B–D</bold>
 </xref>).
</p>
